Treatment of COVID-19 Pneumonia in Hospitalized Patients with Mild-to-Moderate Disease at High Risk for Progression to Severe Illness

Clinical Scenario

This protocol applies to the hospitalized patient with mild-to-moderate COVID-19 — defined as SpO2 greater than 94% on room air, not requiring supplemental oxygen — who is at high risk for progression to severe disease and presents within 7 days of symptom onset.

Patient Population

The defining feature of this population is preserved oxygenation without supplemental support, combined with recognised risk factors that increase the likelihood of clinical deterioration. Early intervention within the established symptom window is central to the recommended approach.

Treatment approach The evidence-based strategy for this population involves early antiviral therapy initiated within the defined symptom window. The complete regimen, dosing criteria, and eligibility details are available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/cid/ciac724

Among patients (ambulatory or hospitalized) with mild-to-moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests remdesivir initiated within 7 days of symptom onset rather than no remdesivir.

Mild-to-moderate illness is defined as patient with SpO2 >94% not requiring supplemental oxygen.

View source ↗